Literature DB >> 15632911

Survival outcomes for second primary head and neck cancer: a matched analysis.

Neil Bhattacharyya1, Vijay K Nayak.   

Abstract

OBJECTIVE: Determine whether survival for second primary head and neck cancer is truly poorer than survival for first primaries.
METHODS: From the Surveillance, Epidemiology and End Results database, 2 cohorts were constructed. One cohort consisted of patients with exactly 1 head and neck primary malignancy; the second cohort consisted of patients with exactly 2 head and neck primaries, restricted to second primaries of the tongue, tonsil, glottic larynx, and hypopharynx with squamous cell carcinoma (SCCA) histology. Demographic and extent of disease data were extracted. For each primary site, matched Kaplan-Meier survival analysis was conducted comparing overall survival between the two cohorts matching for primary site, year of diagnosis, age, gender, and cancer stage.
RESULTS: A total of 242 cases of second head neck primary were successfully matched to patients with single primary disease. Among 96 patients with oral tongue SCCA, mean (median) survival was 40.1 (28) months after the second primary diagnosis versus 52.2 (32) months for matched single primary patients ( P = 0.552, log-rank test). Among 45 tonsillar carcinomas, mean survival was 42.8 (30) versus 90.9 (NA) months for the second primary and single primary cohorts, respectively ( P = 0.028). Among 52 matched glottic carcinomas, mean survival was 46.4 (27) versus 103.5 (120) months for the 2 cohorts, respectively ( P < 0.001). Among 49 hypopharyngeal carcinomas, mean survival was 35.6 (19) versus 53.9 (21) months, respectively ( P = 0.373).
CONCLUSIONS: Survivals for second primary head and neck malignancies may be poorer than survivals for comparable first primaries, but in this analysis we did not find this difference to be statistically significant for all subsites. Second primary survival will vary from site to site. EBM RATING: B-3.

Entities:  

Mesh:

Year:  2005        PMID: 15632911     DOI: 10.1016/j.otohns.2004.08.011

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines.

Authors:  Jason S White; Joel L Weissfeld; Camille C R Ragin; Karen M Rossie; Christa Lese Martin; Michele Shuster; Chandramohan S Ishwad; John C Law; Eugene N Myers; Jonas T Johnson; Susanne M Gollin
Journal:  Oral Oncol       Date:  2006-11-16       Impact factor: 5.337

2.  Prevalence and Outcomes of Head and Neck versus Non-Head and Neck Second Primary Malignancies in Head and Neck Squamous Cell Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database.

Authors:  Andrew C Birkeland; Andrew J Rosko; Steven B Chinn; Mark E Prince; Gordon H Sun; Matthew E Spector
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2016-02-25       Impact factor: 1.538

Review 3.  Open questions and novel concepts in oral cancer surgery.

Authors:  Giancarlo Tirelli; Serena Zacchigna; Matteo Biasotto; Marco Piovesana
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-24       Impact factor: 2.503

4.  Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers.

Authors:  Brandon W Peck; Kristina R Dahlstrom; Samuel J Gan; Wes Caywood; Guojun Li; Qingyi Wei; Mark E Zafereo; Erich M Sturgis
Journal:  Head Neck       Date:  2012-06-19       Impact factor: 3.147

5.  Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers.

Authors:  Samuel J Gan; Kristina R Dahlstrom; Brandon W Peck; Wes Caywood; Guojun Li; Qingyi Wei; Mark E Zafereo; Erich M Sturgis
Journal:  Cancer       Date:  2013-04-19       Impact factor: 6.860

6.  Value of oesophagoscopy and bronchoscopy in diagnosis of synchronous malignancies in patients with head and neck squamous cell carcinomas.

Authors:  Shi Yeung Ho; Raymond King Yin Tsang
Journal:  BMC Cancer       Date:  2020-12-01       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.